Cannabis Bioscience International Holdings (CBIH) Secures Texas Hemp License, Initiates VitaCookies Market Launch

Texas License Approval Enables Hemp Product Manufacturing and Distribution for CBIH

In its July 15, 2026 statement, Cannabis Bioscience International Holdings confirmed that the State of Texas has officially approved its license to manufacture and distribute consumable hemp products within Texas. This approval marks a significant regulatory achievement for CBIH, which has been progressing through scientific research, product formulation, quality assurance, and compliance efforts over several years leading up to this point.

For investors following the company’s development, this license shifts CBIH from a pre-commercial phase to one legally permitted to launch hemp-derived consumable products commercially. The company indicated it will "step into the market and begin commercial distribution" as a direct consequence of this approval, signaling a substantial operational shift. Details regarding licensing fees, total approval costs, or the full range of covered products beyond consumable hemp items were not disclosed.

VitaCookies: CBIH’s Initial Consumer Product Launch

The company’s first commercial rollout centers on VitaCookies, described as a "market-ready functional wellness cookie line." The product incorporates select cannabinoid and nutritional ingredients developed through a disciplined process involving formulation, regulatory compliance, quality control, and consumer innovation. VitaCookies targets wellness segments including menopause support, everyday discomfort relief, stress management, relaxation, emotional balance, and mental well-being.

VitaCookies represents more than a single product launch; it exemplifies CBIH’s integrated business model combining cannabinoid innovation, scientific development, intellectual property, brand creation, and scalable distribution. The company views VitaCookies as a foundation for generating revenue, expanding its portfolio, and creating long-term shareholder value. The announcement did not provide details on unit pricing, sales projections, distribution partners, or revenue targets.

Commercial Distribution to Begin Within 30 Days

The announcement specifies an expectation that initial distribution will start within 30 days of July 15, 2026, aiming for operations to commence by mid-August 2026, barring delays. This timeline reflects years of scientific development, product formulation, regulatory preparation, and commercialization planning.

While this 30-day target offers a near-term milestone for investors, it remains forward-looking and subject to risks and uncertainties outlined in the company’s forward-looking statements disclaimer. The announcement did not specify the geographic scope within Texas, existing distribution agreements, or inventory volumes prepared for launch.

Federal Cannabis Rescheduling Hearings Conclude Concurrently with Texas License Announcement

The company highlighted that its announcement coincided with the conclusion of federal hearings on July 15, 2026, regarding the proposed cannabis rescheduling from Schedule I to Schedule III. CBIH expressed optimism that this process "could help advance a more science-based regulatory framework, expand opportunities for cannabinoid research, and create a clearer path for responsible commercial innovation across the industry."

It is important to note that the rescheduling process has not yet been finalized or confirmed; the hearings have ended without a regulatory decision detailed in the release. CBIH’s commentary reflects its perspective and expectations rather than confirmed outcomes. Nonetheless, the timing is portrayed as significant, and investors in the cannabinoid and hemp sectors may interpret this concurrence as indicative of potential regulatory progress. Stakeholders should independently monitor official sources for updates on federal rescheduling.

CEO Dante Picazo Describes License as a Milestone in CBIH’s Strategic Vision

CEO Dante Picazo characterized the Texas license approval as a transformative event, stating: "Receiving our Texas license at one of the most consequential turning points in modern cannabis history transforms this achievement into something far greater than regulatory approval. It marks the moment when preparation becomes execution, science moves closer to the consumer, and long-term vision enters the marketplace."

Picazo further expressed confidence that "2026 will be remembered as the year the industry began to redefine itself," positioning CBIH as an active contributor to the sector’s evolution. These remarks are forward-looking and subject to risks and uncertainties that could affect actual results.

R&D Director Highlights Scientific Progress Underpinning License Achievement

Dr. Rosangel Andrades, CBIH’s Research and Development Director, emphasized the importance of translating scientific knowledge into innovation and commercial products. She stated: "The future of cannabis will be shaped not only by cultivation and regulation, but also by the ability to convert scientific knowledge into protected innovation and commercially viable products. For CBIH, this license marks the point at which years of research, formulation, and strategic preparation move into execution."

Dr. Andrades added that "the Company is no longer building toward market entry; it is entering the market with a platform designed to connect cannabinoid science, consumer wellness, and long-term commercial value." The company did not disclose specific intellectual property holdings or proprietary formulation details.

CBIH’s Integrated Business Model: Linking Science, IP, and Scalable Distribution

Throughout the announcement, CBIH emphasizes its integrated business model, which combines cannabinoid innovation, scientific development, intellectual property, brand creation, and scalable distribution infrastructure. VitaCookies is positioned as the initial commercial expression of this model, with plans for portfolio expansion mentioned.

The reference to scalable distribution and portfolio growth suggests VitaCookies may be the first of multiple hemp-derived wellness products, though no further product details or launch timelines were provided. Investors should view this as strategic framing rather than confirmed operational specifics.

Wellness Market Positioning Amidst Competitive Hemp Consumer Goods Landscape

VitaCookies targets wellness sub-categories aligned with current consumer health trends, including menopause support, pain relief, stress management, relaxation, emotional balance, and mental well-being. These segments are among the fastest-growing in the functional food and wellness markets. Texas, as one of the largest U.S. consumer markets by population, represents a significant opportunity.

However, the hemp-derived consumable goods sector is competitive, with numerous established brands in functional foods, CBD edibles, and wellness cookies. The company did not disclose market share goals, competitive analyses, or consumer research supporting its positioning. Investors should independently evaluate competitive dynamics when assessing CBIH’s commercial prospects.

OTC Markets Listing and Investor Advisory

Cannabis Bioscience International Holdings is listed on OTC Markets under the ticker CBIH and holds an OTCID designation. OTC Markets hosts companies at various development and compliance stages, and investors should be aware that disclosure standards, liquidity, and trading volumes may differ significantly from those on major exchanges like TSX, NYSE, or Nasdaq. The company directs investors to its filings on OTCmarkets.com for risk factors and regulatory disclosures.

The immediate impact on share price was unclear at the time of writing. As with all small-cap and development-stage cannabinoid companies, investors are advised to thoroughly review regulatory filings, financial statements, and management commentary before investing. The announcement includes standard forward-looking statements disclaimers, with no obligation for the company to update these statements as circumstances evolve.